Current Clinical Pharmacology

Arduino A. Mangoni
Flinders University and Flinders Medical Centre
Adelaide, SA


CD26: A Multi-Purpose Pharmacological Target

Author(s): Formica Vincenzo, Tesauro Manfredi, Cardillo Carmine and Roselli Mario

Affiliation: Medical Oncology Unit, Internal Medicine Department, University Hospital 'Tor Vergata' , Viale Oxford, 81, 00133 Rome, Italy.


CD26 is a widely expressed transmembrane glycoprotein with peptidase activity in its extracellular domain and which regulates multiple biological processes.

It acts mainly as catabolic enzyme for a number of circulating proteins involved in common pathological conditions such as diabetes and cardiovascular disease and may represent a target to modulate bioavailability of crucial substrates.

The aim of the present review is to summarize data regarding CD26-based pharmacological interventions. Four main subtopics were identified:1) CD26 as the target of pharmacological inhibitors to increase bioavailability of glucagon-like petide-1 (GLP-1) and hence to enhance GLP-1 glucose-lowering activity in diabetic patients; 2) role of CD26 in the physiology and pathology of the cardiovascular system; 3) the adverse prognostic value of CD26 expression on cancer cells; 4) CD26 down-regulation on lymphocytes as a mechanism of TGF-beta immunomodulation.

Keywords: CD26, colorectal cancer, dipeptidyl peptidase 4, glucagon-like petide-1, stromal cell-derived factor-1.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [157 - 164]
Pages: 8
DOI: 10.2174/1574884708666131111201654